BioCryst Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 86.74 million compared to USD 75.83 million a year ago. Net loss was USD 36.15 million compared to USD 42.52 million a year ago. Basic loss per share from continuing operations was USD 0.19 compared to USD 0.23 a year ago.
For the nine months, revenue was USD 238.01 million compared to USD 191.28 million a year ago. Net loss was USD 164.81 million compared to USD 175.58 million a year ago. Basic loss per share from continuing operations was USD 0.87 compared to USD 0.95 a year ago.